Supply Chain Intelligence

Zenas BioPharma, Inc. Supply Chain

ZBIO supply chain intelligence for Zenas BioPharma, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

ZBIO ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

17Suppliers
30Customers
2Debt Items
20Related Chains

Source-Backed Evidence Depth

Zenas BioPharma, Inc. (ZBIO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

60Total relationships
3Distinct source URLs
8High confidence
0.722Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Zenas BioPharma, Inc. Suppliers

TickerNameConfidenceEvidence
INNOCARE INNOCARE 92% our collaboration partner, InnoCare, for the supply of orelabrutinib, ZB021 and ZB022, for use in our preclinical and clinical trials
PHARMAKON-ADVISORS-LP PHARMAKON-ADVISORS-LP 92% The Company alleviated the uncertainty associated with its ability to continue as a going concern through the execution of its senior secured term loan, the issuance of Convertible Notes and the seni…
WUXI-BIOLOGICS WUXI-BIOLOGICS 92% We maintain a master services agreement with Wuxi Biologics pursuant to which it provides biologics development and manufacturing services on
AZN AstraZeneca PLC 72% embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact…
AZN AstraZeneca PLC 72% Reciprocal relationship from AZN graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from AZN graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from AZN grap…
BMY Bristol-Myers Squibb Company 72% Reciprocal relationship from BMY graph: from the date of issuance. As of March 31, 2026 and December 31, 2025, we had a five-year $5.0 billion revolving credit facility, which is extendable annually …
BMYMP Bristol-Myers Squibb Co 72% Reciprocal relationship from BMYMP graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from BMYMP graph: from the date of issuance. As of March 31, 2026 and December 31, 2025, we …
CELG-RI CELG-RI 72% Reciprocal relationship from CELG-RI graph: Reciprocal relationship from ZBIO graph: embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates…
CELG-RI CELG-RI 72% embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact…
CLYM Climb Bio, Inc. 72% Reciprocal relationship from CLYM graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from CLYM graph: ies; • the cost of nonclinical studies and clinical trials of our product ca…
DNTH Dianthus Therapeutics, Inc. 72% Reciprocal relationship from DNTH graph: ature and extent of the potential impacts to our business, results of operations, liquidity and capital resources. For additional information, see the section…
GSK GSK plc 72% Reciprocal relationship from GSK graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from GSK graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from GSK grap…
GSK GSK plc 72% embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact…
NVSEF Novartis AG 72% Reciprocal relationship from NVSEF graph: Reciprocal relationship from ZBIO graph: embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates a…
NVSEF Novartis AG 72% embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact…
VRDN Viridian Therapeutics, Inc. 72% Reciprocal relationship from VRDN graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from VRDN g…
XNCR Xencor, Inc. 72% Reciprocal relationship from XNCR graph: these consolidated financial statements. 77 Xencor, Inc. Notes to Consolidated Financial Statements 1. Summary of Significant Accounting Policies As of Decemb…

Zenas BioPharma, Inc. Customers

TickerNameConfidenceEvidence
INNOCARE-PHARMA-INC INNOCARE-PHARMA-INC 85% ar or identical to ours, and our ability to successfully develop and commercialize our product candidates may be adversely impacted; ● ​ We have relied and expect to continue to rely on third parties…
ZAI-LAB-HONG-KONG-LIMITED ZAI-LAB-HONG-KONG-LIMITED 85% the Company granted Zai an exclusive sublicense to develop, manufacture and commercialize ZB001 and related programs in greater China
AZN AstraZeneca PLC 72% Reciprocal relationship from AZN graph: Reciprocal relationship from ZBIO graph: embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are…
AZN AstraZeneca PLC 72% embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact…
BHC Bausch Health Companies Inc. 72% Reciprocal relationship from BHC graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from BHC graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from BHC grap…
BHC Bausch Health Companies Inc. 72% embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact…
BMY Bristol-Myers Squibb Company 72% embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact…
BMY Bristol-Myers Squibb Company 72% Reciprocal relationship from BMY graph: Reciprocal relationship from ZBIO graph: embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are…
BMYMP Bristol-Myers Squibb Co 72% embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact…
BMYMP Bristol-Myers Squibb Co 72% Reciprocal relationship from BMYMP graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from BMYM…
CELG-RI CELG-RI 72% Reciprocal relationship from CELG-RI graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from ZBIO graph: embly facilities in the U.S. …
CELG-RI CELG-RI 72% embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact…
DNTH Dianthus Therapeutics, Inc. 72% Reciprocal relationship from DNTH graph: . Commercial Should any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States an…
GSK GSK plc 72% Reciprocal relationship from GSK graph: Reciprocal relationship from ZBIO graph: embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are…
GSK GSK plc 72% embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact…
LLY Eli Lilly and Company 72% embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact…
LLY Eli Lilly and Company 72% Reciprocal relationship from LLY graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from LLY grap…
NUVB Nuvation Bio Inc. 72% Reciprocal relationship from NUVB graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from NUVB graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from NUVB g…
NUVB Nuvation Bio Inc. 72% IL-17AA homodimer and IL-17AF heterodimer signaling. We expect Phase 1 clinical study initiation in 2026. ZB022 is an oral, brain-penetrant tyrosine kinase 2 (“TYK2”)-JH2 inhibitor, currently in Inve…
NVSEF Novartis AG 72% Reciprocal relationship from NVSEF graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ZBIO graph: embly facilities in the U.S. or E…
NVSEF Novartis AG 72% embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact…
SNYNF Sanofi 72% also engage in cyber-attacks for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties upon w…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from ZBIO graph: also engage in cyber-attacks for geopolitical reasons and in conjunction with military conflicts and defense activit…
TKPHF Takeda Pharmaceutical Company Limited 72% Reciprocal relationship from TKPHF graph: Reciprocal relationship from ZBIO graph: nt in the US, including the following Phase 3 programs: zasocitinib, a peripheral acting TYK2 inhibitor being develo…
TKPHF Takeda Pharmaceutical Company Limited 72% nt in the US, including the following Phase 3 programs: zasocitinib, a peripheral acting TYK2 inhibitor being developed by Takeda Pharmaceutical Company Limited, envudeucitinib, a brain-penetrant TYK…
VRDN Viridian Therapeutics, Inc. 72% Reciprocal relationship from VRDN graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from ZBIO graph: IL-17AA homodimer and IL-17AF heter…
VRDN Viridian Therapeutics, Inc. 72% IL-17AA homodimer and IL-17AF heterodimer signaling. We expect Phase 1 clinical study initiation in 2026. ZB022 is an oral, brain-penetrant tyrosine kinase 2 (“TYK2”)-JH2 inhibitor, currently in Inve…
BHVN Biohaven Ltd. 62% Reciprocal relationship from BHVN graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from BHVN graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from BHVN g…
BIOHAVEN-THERAPEUTICS-LTD BIOHAVEN-THERAPEUTICS-LTD 62% nt in the US, including the following Phase 3 programs: zasocitinib, a peripheral acting TYK2 inhibitor being developed by Takeda Pharmaceutical Company Limited, envudeucitinib, a brain-penetrant TYK…
BPCR-LIMITED BPCR-LIMITED 62% g, distribution, licensing or other strategic arrangements with third parties on favorable terms, if at all; 152 Table of Contents ● our ability to achieve sufficient market acceptance, coverage and …

Zenas BioPharma, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
ZBIO-DEBT-13734 Xbrl Convertible 90% xbrl convertible detail from xbrl 2024-12-31.
ZBIO-DEBT Debt stack $78.6M 90% Market cache reports total debt of $78.6M.

Zenas BioPharma, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Zenas BioPharma, Inc..

Zenas BioPharma, Inc. Ownership

HolderNameConfidenceEvidence
ZBIO-OWNER-FMR-LLC FMR LLC 90% 13F overlay lists FMR LLC as top holder; 140 tracked holders.

Zenas BioPharma, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
CBIO Crescent Biopharma, Inc. 100.00 2
CCCC C4 Therapeutics, Inc. 100.00 2
SVA Sinovac Biotech Ltd. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
BLRX BioLineRx Ltd. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
DAWN Day One Biopharmaceuticals Inc 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
AXSM Axsome Therapeutics, Inc. 100.00 2
CRBP Corbus Pharmaceuticals Holdings, Inc. 100.00 2
DEO Diageo plc 100.00 2
EMMA Emmaus Life Sciences, Inc. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
CLYM Climb Bio, Inc. 100.00 1 ['supplier']
BIOA BioAge Labs, Inc. 100.00 2
CYTK Cytokinetics, Incorporated 100.00 2
FHTX Foghorn Therapeutics Inc. 100.00 2
BEAM Beam Therapeutics Inc. 100.00 2
CCEP Coca-Cola Europacific Partners PLC 100.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for Zenas BioPharma, Inc..

Unlock full ZBIO data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
ZBIO
Unlock ZBIO Supply Chain Data
Verified relationships include:
INNOCAREINNOCARESupplier92%
PHARMAKON-ADVISORS-LPPHARMAKON-ADVISORS-LPSupplier92%
INNOCARE-PHARMA-INCINNOCARE-PHARMA-INCCustomer85%
ZAI-LAB-HONG-KONG-LIMITEDZAI-LAB-HONG-KONG-LIMITEDCustomer85%
+46 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →